Tag Archives: Gilead Sciences

Cantor Fitzgerald Keeps a Buy Rating on Gilead Sciences (GILD)

In a report released today, Alethia Young from Cantor Fitzgerald reiterated a Buy rating on Gilead Sciences (GILD – Research Report), with a price target of $86.00. The company’s shares closed last Monday at $77.73. According to TipRanks.com, Young is

Gilead Sciences (GILD) Receives a Buy from Oppenheimer

Oppenheimer analyst Hartaj Singh maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $80.00. The company’s shares closed last Thursday at $76.98. According to TipRanks.com, Singh is a 4-star analyst with

RBC Capital Maintains Their Buy Rating on Gilead Sciences (GILD)

RBC Capital analyst Brian Abrahams maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $83.00. The company’s shares closed last Monday at $74.52. According to TipRanks.com, Abrahams is a 4-star analyst

Analysts Conflicted on These Healthcare Names: Gilead Sciences (NASDAQ: GILD) and Amgen (NASDAQ: AMGN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Gilead Sciences (GILD – Research Report) and Amgen (AMGN – Research Report). Gilead Sciences (GILD) In a report released yesterday, Brian Abrahams from RBC Capital

Maxim Group Sticks to Their Hold Rating for Gilead Sciences (GILD)

In a report issued on February 6, Jason McCarthy from Maxim Group maintained a Hold rating on Gilead Sciences (GILD – Research Report). The company’s shares closed last Monday at $68.87. According to TipRanks.com, McCarthy is a 1-star analyst with

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD) and Zimmer Biomet Holdings (NYSE: ZBH)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD – Research Report) and Zimmer Biomet Holdings (ZBH – Research Report) with bullish sentiments. Gilead Sciences (GILD) In a